- Enhertu demonstrated 61.6% progression-free survival at one year for HER2-positive metastatic breast cancer with brain metastases in DESTINY-Breast12 study.
Fri Sep 13 13:14:51 -0000 2024 UTC– AstraZeneca’s Enhertu displayed significant effectiveness in patients with HER2-positive metastatic breast cancer and brain metastases, achieving a 61.6% progression-free survival rate at one year.
Results have been presented at the European Society for Medical Oncology (ESMO) and simultaneously published in Nature Medicine.
Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
Destiny-Breast12 Study Design
The Destiny-Breast12 is an open-label, multicenter, international Phase IIIb/IV study to evaluate the efficacy and safety of safety of T-DXd in patients with Her2+ breast cancer, with or without brain metastases.
Patients have repeatedly progressed after an anti-HER2-based therapy regimen and have received a maximum of 2 systemic therapies in the advanced setting.
Participants will be randomized at participants are assigned to two different cohorts at the start of the study according to the presence or cohorts according to the presence or absence of brain metastases.
Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:
About Lisa
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter
Read more Business News as it happens!
Business